Twilight Dark-Adaptation Device Now Available in US - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Twilight Dark-Adaptation Device Now Available in US

Evoq Technologies receives official FDA registration as a Class I medical device

  • By

  • mdspire news news staff

  • December 1, 2025

  • 1 min

Share

Objective:

To announce the FDA registration and availability of the Twilight dark-adaptation testing instrument as a Class I medical device.

Approach:
  • Device Overview: Twilight facilitates the detection of age-related macular degeneration (AMD), diabetic eye disease, and inherited retinal disease.
  • Clinical Use: The device can be used by technicians in any clinical setting for quick screening without the need for dark rooms or pupil dilation.
  • Reimbursement: Testing with the device is reimbursable under CPT 92284 for qualifying patients.
Key Findings:
  • Twilight is now available for sale in the United States.
Interpretation:

Conclusion:

Sources:

Original Source(s)

Twilight Dark-Adaptation Device Now Available in US

  • by mdspire news news staff

  • December 1, 2025

Related Content

Stuart Therapeutics Spotlights Topical RP Program

At OIS Retina, Eric Schlumpf discussed the company’s collagen mimetic peptide platform for retinitis pigmentosa, now in preclinical development.

Performance of Deep Learning in Classifying Age-Related Macular Degeneration From Images: Systematic Review and Meta-Analysis

Are GLP-1s Linked to Optic Neuropathy?

A nationwide Swedish cohort found a higher relative risk of anterior ischemic optic neuropathy among GLP-1 receptor agonist users, but the overall risks were low.